Liminatus Pharma, Inc. (LIMN)

Liminatus Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	0.65	0.65	1.06	0.86
Research & Development	2.69	2.69	3.76	1.85
Operating Expenses	3.33	3.33	4.82	2.71
Operating Income	-3.33	-3.33	-4.82	-2.71
Interest Expense	-0.34	-0.34	-0.18	-0.22
Interest & Investment Income	0.12	0.12	0.01	-
Pretax Income	-3.55	-3.55	-4.98	-2.93
Net Income	-3.55	-3.55	-4.98	-2.93
Net Income to Common	-3.55	-3.55	-4.98	-2.93
Shares Outstanding (Basic)	26	112	102	36
Shares Outstanding (Diluted)	26	112	102	36
Shares Change (YoY)	-74.62%	9.49%	188.25%	-
EPS (Basic)	-0.14	-0.03	-0.05	-0.08
EPS (Diluted)	-0.14	-0.03	-0.05	-0.08
EBIT	-3.33	-3.33	-4.82	-2.71

Source: S&P Global Market Intelligence. Standard template. Financial Sources.